[HTML][HTML] Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors–A phase I trial
CL Lorentzen, E Martinenaite, JW Kjeldsen… - Frontiers in …, 2022 - frontiersin.org
Background Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by
reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of …
reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of …
[HTML][HTML] Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
AH Kverneland, CA Chamberlain… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has
shown remarkable results in malignant melanoma (MM), while studies on the potential in …
shown remarkable results in malignant melanoma (MM), while studies on the potential in …
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF® 09b, in patients with metastatic melanoma
The majority of neoantigens arise from unique mutations that are not shared between
individual patients, making neoantigen-directed immunotherapy a fully personalized …
individual patients, making neoantigen-directed immunotherapy a fully personalized …
[HTML][HTML] First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer
SK Mørk, P Kongsted, MCW Westergaard… - Frontiers in …, 2023 - frontiersin.org
Background The B-cell lymphoma-extra-large (Bcl-XL) protein plays an important role in
cancer cells' resistance to apoptosis. Pre-clinical studies have shown that vaccination with …
cancer cells' resistance to apoptosis. Pre-clinical studies have shown that vaccination with …
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
SK Mørk, SK Skadborg, B Albieri, A Draghi… - 2023 - ascopubs.org
9551 Background: Despite the advances made with CPIs such as aPD-1/aPD-L1, aCTL4
and aLAG-3 there still is a significant unmet medical need for patients with metastatic …
and aLAG-3 there still is a significant unmet medical need for patients with metastatic …